HODGKINS-DISEASE - BASING TREATMENT DECISIONS ON PROGNOSTIC FACTORS

被引:6
作者
FAGUET, GB
机构
[1] Depts of Medicine and Biochemistry and Mol. Biology, Medical College of Georgia, Hematology/Oncology and Cancer Immunology Research Laboratory, VA Medical Center, Augusta, GA
关键词
HODGKINS DISEASE; TREATMENT DECISIONS; PROGNOSTIC FACTORS;
D O I
10.3109/10428199509056826
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to review the current status of risk factor assessment in Hodgkin's disease (HD) clinically useful for managing this disease. Regarding database retrieval and selection a literature search restricted to English-language articles, abstracts, book chapters and reports published between 1980 and 1993 was conducted both electronically using MEDLINE and CANCERLIT and manually using the bibliographies of the retrieved database. Out of approximately 500 publications identified for analysis, 34 were selected as illustrative. Results showed that most patients with Hodgkin's disease are curable at the outset with standard radio- or chemo-therapy, depending on stage and other risk factors. However, up to 40% of patients will either fail at initial induction, or experience early or late relapses. Risk factors analysis at these various times provide a solid base for selecting the therapy best suited to optimize outcome for each individual patient. Patients with truly refractory disease pose a serious challenge to clinicians and are best managed in specialized centers conducting controlled clinical trials. In conclusion it appears that although approximately 75% of newly diagnosed patients with HD can expect long-term, disease-free survival, refractory patients exhibit a dismal survival. Improving their outcome will require innovative approaches.
引用
收藏
页码:223 / 228
页数:6
相关论文
共 34 条
  • [1] Urba W.J., Longo D.L., Hodgkin's disease, N. Engl. J. Med., 326, (1992)
  • [2] Faguet G.B., Davis H.C., Survival in Hodgkin's disease: the role of immunocompetence and other risk factors, Blood, 59, (1982)
  • [3] Lister T.A., Crowther D., Sutcliffe S.B., Et al., Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting, J. Clin. Oncol., 8, (1990)
  • [4] Tirelli U., Errante D., Vaccher E., Et al., Hodgkin's disease in 92 patients with HIV infection: The Italian experience, Ann. Oncol., 3, (1992)
  • [5] Hopper K.D., Diehl L.F., Lesar M., Et al., Hodgkin's disease: clinical utility of CT in initial staging and treatment, Radiology, 169, (1988)
  • [6] Mansfield C.M., Fabian C., Jones S., Et al., Comparison of lymphangiography and computed tomography scanning in evaluating abdominal disease in stages III and IV Hodgkin's disease, Cancer, 66, (1990)
  • [7] Hagemeister F.B., Fesus S.M., Lamki L.M., Et al., The role of the gallium scan in Hodgkin's disease, Cancer, 65, (1990)
  • [8] Bergsagel D.E., Alison R.E., Bean H.A., Et al., Results of treating Hodgkin's disease without a policy of laparotomy staging, Cancer Treat Rep., 61, (1982)
  • [9] Ambrosetti A., Nadali G., Vinante F., Et al., Serum levels of soluble interleukin-2 receptor in Hodgkin's disease. Relationship with clinical stage, tumor burden and treatment outcome, Cancer, 72, (1993)
  • [10] Kurzrock R., Redman J., Cabanillas F., Et al., Serum inter-leukin-6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease with B symptoms, Cancer Res., 53, (1993)